RYTM Projected Dividend Yield
Rhythm Pharmaceuticals Inc ( NASDAQ : RYTM )Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company to transform the lives of patients and their families living with rare diseases. Co. is focused on developing IMCIVREE® (setmelanotide), as a medicine designed to treat hyperphagia and severe obesity caused by melanocortin-4 receptor pathway diseases. IMCIVREE is approved by the U.S. Food and Drug Administration for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to: proopiomelanocortin, proprotein convertase subtilisin/kexin type 1 or leptin receptor deficiency; or Bardet-Biedl syndrome. 20 YEAR PERFORMANCE RESULTS |
RYTM Dividend History Detail RYTM Dividend News RYTM Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |